JP2024540183A - 置換されたフェニルプロピオン酸誘導体及びその使用 - Google Patents
置換されたフェニルプロピオン酸誘導体及びその使用 Download PDFInfo
- Publication number
- JP2024540183A JP2024540183A JP2024525662A JP2024525662A JP2024540183A JP 2024540183 A JP2024540183 A JP 2024540183A JP 2024525662 A JP2024525662 A JP 2024525662A JP 2024525662 A JP2024525662 A JP 2024525662A JP 2024540183 A JP2024540183 A JP 2024540183A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- independently selected
- medicamentable
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111293711.9 | 2021-11-03 | ||
| CN202111293711 | 2021-11-03 | ||
| CN202211033065 | 2022-08-26 | ||
| CN202211033065.7 | 2022-08-26 | ||
| PCT/CN2022/129479 WO2023078333A1 (zh) | 2021-11-03 | 2022-11-03 | 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540183A true JP2024540183A (ja) | 2024-10-31 |
| JP2024540183A5 JP2024540183A5 (https=) | 2026-03-19 |
Family
ID=86240694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525662A Pending JP2024540183A (ja) | 2021-11-03 | 2022-11-03 | 置換されたフェニルプロピオン酸誘導体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250042847A1 (https=) |
| EP (1) | EP4428129A4 (https=) |
| JP (1) | JP2024540183A (https=) |
| KR (1) | KR20240091010A (https=) |
| CN (1) | CN118055927A (https=) |
| AU (1) | AU2022381258A1 (https=) |
| CA (1) | CA3235992A1 (https=) |
| MX (1) | MX2024005304A (https=) |
| TW (1) | TW202334116A (https=) |
| WO (1) | WO2023078333A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119894882A (zh) * | 2023-04-21 | 2025-04-25 | 深圳信立泰药业股份有限公司 | 一种叔胺类化合物及其制备方法和医药用途 |
| WO2024230805A1 (zh) * | 2023-05-11 | 2024-11-14 | 江苏恒瑞医药股份有限公司 | 一种脂蛋白化合物晶型及其制备方法 |
| WO2025024218A1 (en) * | 2023-07-21 | 2025-01-30 | Eli Lilly And Company | PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY |
| WO2025024210A1 (en) * | 2023-07-21 | 2025-01-30 | Eli Lilly And Company | Piperidine, morpholine and tetrahydro-pyridazine compounds with lp(a) lowering activity |
| CN119490445A (zh) * | 2023-08-15 | 2025-02-21 | 深圳信立泰药业股份有限公司 | 一种酰基类化合物及其制备方法和医药用途 |
| US20250179055A1 (en) * | 2023-11-17 | 2025-06-05 | Innovstone Therapeutics Limited | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof |
| WO2025108255A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海齐鲁制药研究中心有限公司 | 一种多环类衍生物、其制备方法和应用 |
| WO2025199298A1 (en) | 2024-03-21 | 2025-09-25 | Eli Lilly And Company | BIOMARKER ASSAY TO MEASURE LIPOPROTEIN(a) |
| WO2025237188A1 (zh) * | 2024-05-14 | 2025-11-20 | 石家庄以岭药业股份有限公司 | 一种LP(a)抑制剂化合物及其应用 |
| WO2026061518A1 (zh) * | 2024-09-23 | 2026-03-26 | 上海京新生物医药有限公司 | 一种环状胺衍生物的固体形式、制备方法及药物组合物 |
| CN121609698A (zh) * | 2026-01-30 | 2026-03-06 | 山东京新药业有限公司 | 一种莫伐培林及中间体的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009531312A (ja) * | 2006-03-10 | 2009-09-03 | ファイザー・プロダクツ・インク | ジベンジルアミン化合物および誘導体 |
| JP2011506410A (ja) * | 2007-12-10 | 2011-03-03 | ７ティーエム ファーマ エイ／エス | カンナビノイド受容体モジュレーター |
| WO2020247429A1 (en) * | 2019-06-07 | 2020-12-10 | Eli Lilly And Company | Pyrrolidine compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1894195A (zh) * | 2000-10-11 | 2007-01-10 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的醚化合物以及组合物 |
| CA2425311C (en) * | 2000-10-11 | 2011-06-14 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| US7371777B2 (en) * | 2001-08-17 | 2008-05-13 | Eisai Co., Ltd. | Cyclic compound and PPAR agonist |
| AU2003300438A1 (en) * | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| JP2007525408A (ja) * | 2003-12-24 | 2007-09-06 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理および関連使用のためのケトン化合物および組成物 |
| WO2023146785A1 (en) * | 2022-01-26 | 2023-08-03 | Eli Lilly And Company | Pyrrolidine compounds |
-
2022
- 2022-11-03 WO PCT/CN2022/129479 patent/WO2023078333A1/zh not_active Ceased
- 2022-11-03 CA CA3235992A patent/CA3235992A1/en active Pending
- 2022-11-03 CN CN202280066584.5A patent/CN118055927A/zh active Pending
- 2022-11-03 KR KR1020247017510A patent/KR20240091010A/ko active Pending
- 2022-11-03 EP EP22889355.8A patent/EP4428129A4/en active Pending
- 2022-11-03 MX MX2024005304A patent/MX2024005304A/es unknown
- 2022-11-03 TW TW111142050A patent/TW202334116A/zh unknown
- 2022-11-03 US US18/707,429 patent/US20250042847A1/en active Pending
- 2022-11-03 AU AU2022381258A patent/AU2022381258A1/en active Pending
- 2022-11-03 JP JP2024525662A patent/JP2024540183A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009531312A (ja) * | 2006-03-10 | 2009-09-03 | ファイザー・プロダクツ・インク | ジベンジルアミン化合物および誘導体 |
| JP2011506410A (ja) * | 2007-12-10 | 2011-03-03 | ７ティーエム ファーマ エイ／エス | カンナビノイド受容体モジュレーター |
| WO2020247429A1 (en) * | 2019-06-07 | 2020-12-10 | Eli Lilly And Company | Pyrrolidine compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024005304A (es) | 2024-05-17 |
| CA3235992A1 (en) | 2023-05-11 |
| CN118055927A (zh) | 2024-05-17 |
| EP4428129A1 (en) | 2024-09-11 |
| US20250042847A1 (en) | 2025-02-06 |
| EP4428129A4 (en) | 2025-05-07 |
| WO2023078333A1 (zh) | 2023-05-11 |
| KR20240091010A (ko) | 2024-06-21 |
| WO2023078333A8 (zh) | 2023-08-10 |
| TW202334116A (zh) | 2023-09-01 |
| AU2022381258A1 (en) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540183A (ja) | 置換されたフェニルプロピオン酸誘導体及びその使用 | |
| JP7813970B2 (ja) | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 | |
| JP7579805B2 (ja) | アミノ酸化合物の剤形およびレジメン | |
| JP7508422B2 (ja) | ピロリジン化合物 | |
| JP3993651B2 (ja) | シクロプロパクロメンカルボン酸誘導体 | |
| EP4332102A1 (en) | Isoquinolone compound and use thereof | |
| JPH07502265A (ja) | 酸化窒素供与体プロドラッグとしての求核試薬−酸化窒素付加物の酸素置換誘導体 | |
| JPH07223953A (ja) | 中枢神経系疾患治療用薬剤組成物 | |
| JP2024032976A (ja) | アデノシン受容体アンタゴニストおよびその使用 | |
| JP2026502915A (ja) | 補体因子ｂ阻害剤 | |
| WO2014013469A1 (en) | Carbamate/urea derivatives | |
| JP2024535804A (ja) | 置換された１，４－ジヒドロ－１，６－ナフチミダミド及びその使用 | |
| AU2024267706A1 (en) | Crystal form of lipoprotein compound and preparation method therefor | |
| JPS6112907B2 (https=) | ||
| CN115677507B (zh) | 氟比洛芬衍生物及其在药物中的应用 | |
| JP7701475B2 (ja) | アルキルカルボン酸化合物及びその使用 | |
| JP2024535126A (ja) | 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途 | |
| JP2024533411A (ja) | ハロゲン置換のピリダジノン系化合物及びその使用 | |
| PT93045A (pt) | Processo para a preparacao de derivados de pirrolidina e de composicoes farmaceuticas que os contem | |
| KR20150135281A (ko) | 페닐 유도체 | |
| TW202515554A (zh) | Slc6a19功能之含雙環雜芳基之哌啶抑制劑 | |
| JP3786983B2 (ja) | ピロリジノン誘導体 | |
| CN114621189B (zh) | 一种内酰胺类衍生物及其用途 | |
| WO2001000616A1 (en) | Cholesterol biosynthesis inhibitors containing as the active ingredient aromatic compounds bearing cyclic amino groups | |
| CN114621190B (zh) | 一种烯丙基胺类衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251031 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260310 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20260310 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260331 |